Member Info for RayPointer

Yes, if Covidity is effective, it would be government money well spent in funding the next stages. Scancell would still need a pharma partner to get it into production.
Think of the kudos Boris and Co would get and it would mean that he could sneak through another refurbishment of the no 10 flat without any fuss :-)

You're dead right shorn.
But the best advert of Jube's ESG credentials would be to clean up Kabwe.

This is an old article but it clearly explains that big pharma are often slow to catch on to great discoveries.

https://www.nbcnews.com/health/health-news/nobel-winner-fought-drug-company-interest-cancer-discovery-n915446

Now checkpoint inhibitors are all the rage and earning big pharma billions in revenue.

With immunobody, it is hoped that Covidity will attract great interest from big pharma.
But let's not forget that Immunobody in the form of SCIB1 is also getting another outing this year. So we have the possibility of a double whammy. Of course, if Covidity is successful it will get all the publicity. Let's not forget that SCIB1 in combination with a CI may also prove to be a great breakthrough in the fight against cancer.

The point is that moditope can target multiple epitopes from multiple proteins.
Citrullination and Homo-citrullination can occur in different epitopes on different proteins.
I think from memory Lindy had discovered in the order of 30 different citrullinated epitopes. She narrowed it down to the most promising 3 epitopes for Modi1. So the chance that an individual patient expresses none of these 3 epitopes is hopefully quite small.

I think in time the market will wake up to the fact that there are huge amounts of tailings lying around just waiting to the processed. The companies that can do this efficiently will at some point attract a high PE rating.
When a comparison is made to conventional mining
1) No exploration costs
2) Much lower expenditure to reach a stage when you can extract the metals
3) Much smaller timescales to reach the production stage
All in all, there is far less risk in processing tailings.

"'5. Additional potential solutions are to invest in developing new vaccination strategies that
could induce stronger T cell responses since T cell epitopes might vary less over time."

It certainly seems like an immunobody vaccine fits the bill.

https://www.scancell.co.uk/immunobody

"The most important aspect of the ImmunoBody® technology is the ability to initiate both direct and cross-presentation of epitopes to T cells. There are various pathways by which dendritic cells can process antigen, but the highest avidity T cell responses (i.e., the most potent) are generated if more than one pathway is used to present the same epitope. In the case of ImmunoBody®, the DNA form is taken up and processed directly by dendritic cells whereas the protein form (which is produced from the DNA in cells at the site of the injection) binds to the high affinity Fc receptor on dendritic cells leading to cross-presentation. As a result of both the direct and cross-presentation, the T cells not only have a higher avidity (up to 100-fold increased potency), but there are many more T cells generated against the epitopes of interest."

That would be a pressure cooker

I always find it hard to paint ceilings :-)

Scancell have completed the process to create the viral vector which allows them to generate T Cells that can then be cloned and infused back into the patient.
However, they have found that the cloned T Cells do not have the necessary avidity to make them effective.
They haven't tested all of the possible T Cell epitopes so in Lindy's words "they may get lucky on any of those remaining epitopes"

So they are planning to repeat the process once they have human T Cells activated by Modi1.
One way of looking at this is that, if Modi1 is shown to be effective, then the Biontech collaboration becomes way more significant.

I would be amazed if Scancell are using the N4P delivery system.

See the section on "Self Assembling Peptides" in Sam Paston's recent article.

https://www.scancell.co.uk/Data/Sites/1/media/docspres/paston-et-al-2021.pdf

Nearly all the references are pointing to work carried out by Prof Dixon's group at Nottingham Uni.

"The tripeptide complexes the DNA into nanoparticles and can be delivered by simple intramuscular injection. This tripeptide formulation has achieved exceptional results in DNA delivery applications in particular in lung, brain,
and has huge potential in vaccine delivery"

And didn't Lindy mention in her AGM presentation that the next step for Covidity was to determine the peptides.

Excellent stuff hasiba.
Much better than the recent Independent article.
It starts with Covidity and ends with CEPI! Perhaps this is an omen :-)

My own view is that JLP are free to consider any project in Cyprus whoever the partner may be.

Hi Shiner
CMRS obviously want to push forward quickly on their "waste to revenue" project (as they call it) in order to fund their exploration program. We already know that Leon is focused on delivering projects quickly so I would expect that we will hear news soon on those possible 16 sites. It seems to be a good fit for the 2 companies.

From CMRS RNS yesterday

https://www.lse.co.uk/rns/CMRS/operations-update-9we2un96r2cxqyo.html

"Prioritisation of prospective copper-gold Joint Venture (JV) projects underway by way of a re-assessment of each of the Company's 16 candidate sites against Jubilee Metals Group JV criteria"

The following 6 months should also keep the momentum going with

1) A full 6 month period with the enhanced processing capability for Chrome and PGMs
2) The 2nd Roan concentrator coming on stream giving more visibility to the market of the eventual earnings contribution
from copper
3) Possible guest appearances of Cobalt and Zinc
4) Elephant 1 is due to start construction in August
5) Possibly construction starts in Cyprus

There will almost certainly be other left field news as Leon seeks out other projects

If it is another Diggle wiggle, it could well be a situation where a director buys on dips knowing that there is no reason to justify a fall in the SP.
Following Scancell's retweet of our worthy Bermuda's tweet, it is possibly a second sign that things are progressing.

Exactly, and it also shows the worthiness of bermuda :-)

Everybody ready for another week of waiting?
Scancell investment psychology, never expect news :-)

Ok Crumbs, that makes sense.

"In a separate venture, the company is also working with the Karolinska Institutet in Sweden, one of the world’s leading medical universities, on a DNA vaccine which will be delivered to the patient's muscle to generate a viral antigen to trigger a reaction from the immune system."

This is the first I've heard of this collaboration. We know there is a collaboration with Karolinska on Moditope. Perhaps another piece of bad journalism?